Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955395 | 0.82 | SMN1; SMN2 (0.40) | CHRM1CHRM4CHRM5MAPK1SMN1; SMN2 | |
| SCHEMBL7666262 | 0.79 | SMN1; SMN2 (0.41) | CHRM1CHRM4CHRM5MAPK1SMN1; SMN2 | |
| SCHEMBL7666266 | 0.79 | KMT2A (0.51) | MAPK1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL9650536 | 0.78 | CYP2B6 (0.46) | CHRM1CHRM4CHRM5MAPK1SMN1; SMN2 | |
| SCHEMBL1576239 | 0.76 | MAPK1 (0.76) | MAPK1KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL17523153 | 0.75 | BLM (0.59) | KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL22106794 | 0.75 | MEN1 (0.42) | CHRM3KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL17523154 | 0.74 | MGLL (0.56) | MAPK1SMN1; SMN2KMT2AALDH1A1LMNA | |
| Trifluoroacetic Acid SCHEMBL27851789 | 0.73 | CHRM3 (0.47) | CHRM1CHRM4CHRM3ALDH1A1 | |
| SCHEMBL2867370 | 0.73 | GPR119 (0.53) | CHRM1CHRM4MAPK1SMN1; SMN2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139911-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| CN-107312777-B | Antisense antiviral compounds and methods of treating influenza virus infection | 萨雷普塔治疗公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3023496-B1 | COMPOUNDS WHICH MODULATE INTERLEUKINS 17 AND 23 SIGNALING ACTIVITY | SAREPTA THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10626396-B2 | Antisense composition and method for treating muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10479996-B2 | Antisense antiviral compound and method for treating ss/RNA viral infection | SAREPTA THERAPEUTICS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10144762-B2 | Antibacterial antisense oligonucleotide and method | SAREPTA THERAPEUTICS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180327749-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-11-15 | — | — | US | disclosed |
| US-10006031-B2 | Antisense composition and method for treating muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-2024499-B1 | OLIGONUCLEOTIDE ANALOGS HAVING CATIONIC INTERSUBUNIT LINKAGES | SAREPTA THERAPEUTICS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170247410-A1 | ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-08-31 | — | — | US | disclosed |
| WO-2007030691-A2 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING PICORNAVIRUS INFECTION | AVI BIOPHARMA, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049542-A1 | Antisense antibacterial method and compound | AVI BIOPHARMA, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070037764-A1 | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells | AVI BIOPHARMA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037763-A1 | Inhibiting replication of nidovirus in virus-infected animal cells by exposing cells to oligonucleotide compound having nuclease-resistant backbone, capable of uptake by cells, containing 8-25 nucleotide bases, having sequence complementary to 8 bases in nidovirus' positive-strand genomic rna; sars virus | AVI BIOPHARMA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070004661-A1 | Antisense antiviral compound and method for treating influenza viral infection | NATIONAL INSTITUTES OF HEALTH | 2007-01-04 | — | — | US | disclosed |
| US-20060293268-A1 | Antisense antiviral compounds and methods for treating foot and mouth disease | AVI BIOPHARMA, INC. | 2006-12-28 | — | — | US | disclosed |
| US-20060287268-A1 | Splice-region antisense composition and method | AVI BIOPHARMA, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060281701-A1 | Antisense antiviral compounds and methods for treating a filovirus infection | SAREPTA THERAPEUTICS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-20060276425-A1 | Antisense oligomers and methods for inducing immune tolerance and immunosuppression | SAREPTA THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
| US-20060269911-A1 | Antisense antiviral compound and method for treating ssRNA viral infection | AVI BIOPHARMA, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037763-A1 | Inhibiting replication of nidovirus in virus-infected animal cells by exposing cells to oligonucleotide compound having nuclease-resistant backbone, capable of uptake by cells, containing 8-25 nucleotide bases, having sequence complementary to 8 bases in nidovirus' positive-strand genomic rna; sars virus | SARS1, RNGTT, NSUN2 | CHRM1 4718/4885CHRM4 4407/4885CHRM5 4607/4885 |
| US-10006031-B2 | Antisense composition and method for treating muscle atrophy | MYOF, TNNC1, MTPN | CHRM1 2096/4885CHRM4 1847/4885CHRM5 2314/4885 |
| US-10144762-B2 | Antibacterial antisense oligonucleotide and method | RNGTT, SPOUT1, MRPL21 | CHRM1 4315/4885CHRM4 4265/4885CHRM5 3740/4885 |
| US-10479996-B2 | Antisense antiviral compound and method for treating ss/RNA viral infection | SARS1, SSU72, RNGTT | CHRM1 4154/4885CHRM4 3399/4885CHRM5 3667/4885 |
| US-10626396-B2 | Antisense composition and method for treating muscle atrophy | MYOF, TNNC1, MTPN | CHRM1 2096/4885CHRM4 1847/4885CHRM5 2314/4885 |
| US-20180327749-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | MYOF, TNNC1, MTPN | CHRM1 2096/4885CHRM4 1847/4885CHRM5 2314/4885 |
| US-20070049542-A1 | Antisense antibacterial method and compound | RNGTT, FBL, POLRMT | CHRM1 4881/4885CHRM4 4837/4885CHRM5 4864/4885 |
| US-20070037764-A1 | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells | SAMHD1, POLRMT, HCLS1 | CHRM1 4653/4885CHRM4 4395/4885CHRM5 4617/4885 |
| US-20060281701-A1 | Antisense antiviral compounds and methods for treating a filovirus infection | UPF1, NSUN2, RNGTT | CHRM1 4508/4885CHRM4 4716/4885CHRM5 4776/4885 |
| US-20060293268-A1 | Antisense antiviral compounds and methods for treating foot and mouth disease | EIF2AK2, POLRMT, POLR1C | CHRM1 4097/4885CHRM4 4650/4885CHRM5 4798/4885 |
| US-20170247410-A1 | ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD | RNGTT, SPOUT1, MRPL21 | CHRM1 4315/4885CHRM4 4265/4885CHRM5 3740/4885 |
| US-20210139911-A1 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY | MYOF, TNNC1, MTPN | CHRM1 2096/4885CHRM4 1847/4885CHRM5 2314/4885 |
| US-20060287268-A1 | Splice-region antisense composition and method | RBM17, SNRPA1, SNRPB2 | CHRM1 4878/4885CHRM4 4845/4885CHRM5 4792/4885 |
| US-20070004661-A1 | Antisense antiviral compound and method for treating influenza viral infection | UPF1, RNGTT, NSUN2 | CHRM1 2940/4885CHRM4 2954/4885CHRM5 3069/4885 |
| US-20060276425-A1 | Antisense oligomers and methods for inducing immune tolerance and immunosuppression | CD14, HLA-DRB1, MICA | CHRM1 2633/4885CHRM4 2807/4885CHRM5 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.